Luisa Iruela-Arispe named co-leader of the TEAM Program at Lurie Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Luisa Iruela-Arispe, a vascular biologist, was named co-leader of the Tumor Environment and Metastasis Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. 

The goal of the TEAM Program is to elucidate how interactions between tumor cells, immune cells, and components of the host stromal microenvironment impact tumor development and progression.

Iruela-Arispe is chair of the Department of Cell and Developmental Biology and the Stephen Walter Ranson Professor. Her research focuses on the signaling pathways that regulate vascular morphogenesis during development and pathological settings. Her cancer research interests include the molecular mechanisms that result in the emergence of angiosarcomas and the cross-talk between endothelial and tumor cells in the process of metastasis.

In collaboration with TEAM co-leader, Hidayatullah Munshi, she will help advance efforts to translate basic science discoveries from the TEAM Program into clinical practice.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login